AUMED, established in 2007, specializes in the research and development of innovative immunobiological preparations and pharmaceuticals. Initially focused on other industries, the company shifted to healthcare and pharmaceuticals in response to market demands. Today, AUMED drives pioneering research in advanced treatments, particularly in phage therapy. Its subsidiaries, AUMED Immunology a.s. and Aumed Pharma a.s., further enhance its impact in improving patient care and developing breakthrough therapies for conditions like acne and atopic eczema.
| Website | https://www.aumed.cz |
| Revenue | $5.1 million |
| Employees | 11 (6 on RocketReach) |
| Phone | +420 603 587 701 |
| Industry | Pharmaceutical Manufacturing, Industrial Machinery & Equipment, Manufacturing |
| Keywords | Pharmaceutical Research, Biopharmaceutical Development, Drug Development, Innovative Medicines, Healthcare Products, Immunology Research, Biotechnology, Pharmaceutical Manufacturing, Clinical Trials, Drug Discovery, Life Sciences, Biologics, Therapeutics, Pharmaceutical Sales, Healthcare Innovation, Medical Research, Health Technology, Biotechnology Research, Pharmaceutical |
| Competitors | Johnson & Johnson, Medtronic, Abbott, Stryker, Cardinal Health, Boston Scientific, Zimmer Biomet, Smith+Nephew, B. Braun Group, Terumo +41 more (view full list) |
| SIC | SIC Code 352 Companies, SIC Code 35 Companies |
| NAICS | NAICS Code 333 Companies, NAICS Code 33 Companies |
Looking for a particular Aumed a.s. employee's phone or email?
The Aumed a.s. annual revenue was $5.1 million in 2026.
Juraj Vronka is the CEO of Aumed a.s..
6 people are employed at Aumed a.s..
The NAICS codes for Aumed a.s. are [333, 33].
The SIC codes for Aumed a.s. are [352, 35].